BiosanaPharma announces the launch of its Continuous Manufacturing licensing & implementation offering for the downstream processing of biologics
BiosanaPharma has successfully developed a CM overarching automation platform for 24/7 mAb and non mAb protein manufacturing under GMP
Sydney/Leiden, September 11, 2024 – BiosanaPharma, an Australian/Dutch biotech company, today announced the launch of its Continuous Manufacturing licensing & implementation offering for the downstream processing of biologics. After many years of development and validation work the 3C overarching Continuous Manufacturing automation platform is ready for implementation at third party facilities (CDMOs, Innovators and Biosimilar companies). The key driver is to get more OUTPUT from your existing facility at lower CoGs. Implementation in greenfield plants in combination with 3C upstream perfusion processing is an add-on offering.
Included in the Biosanapharma licensing & implementation offering is automatic sampling and on/at-line analytical, batch to continuous design, equipment procurement, personnel training and implementation at the desired scale (50-500-2000L scale).
Ard Tijsterman, CEO of BiosanaPharma:
“We are very proud that we can now take the next step in the implementation of Continuous Manufacturing at a global scale. CM can solve the capacity issues in existing plants and significantly reduce the overall CoGs in the manufacturing of biologics. The time has come for companies to take the next process development and manufacturing step."
About BiosanaPharma:
BiosanaPharma is a biotechnology company with operations in Australia and The Netherlands. The company is headed by a team of entrepreneurs on a mission to make mAbs and non mAb proteins more affordable and accessible for patients through smart, disruptive technology.
For more information, please have a look at https://www.biosanapharma.com, or contact:
Menne Zaalberg, Chief Operations Officer BiosanaPharma